Clinical Trial Plan for Breast Cancer Phase 2 Approved in Czech Republic by Daehwa Je-yak
[Asia Economy Reporter Minji Lee] Daehwa Pharmaceutical announced on the 24th that it has received approval for a Phase 2 clinical trial plan of DHP107 (oral paclitaxel) for patients with recurrent or metastatic breast cancer in the Czech Republic.
Hot Picks Today
"Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- "Striking Will Lead to Regret": Hyundai-Kia Employees Speak Out... Uneasy Stares Toward Samsung Union
- Man in His 50s Arrested for Confining Girlfriend in Car After She Announced Breakup
- Assaulted by Elementary Student During Class... No Protection Due to 'Instructor' Status
- "If You Booked This Month, You Almost Lost Out... Why You Should Wait Until 'This Day' Before Paying for Flight Tickets"
The company stated, "We plan to verify the safety, tolerability, and efficacy of DHP107 in different ethnic groups," adding, "We aim to start enrolling subjects in the Czech Republic early next year and complete the clinical trial by 2023."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
